The regulatory effects and applications of TIGIT/CD155 on the tumor microenvironment in HCC DOI Creative Commons
W. Li, Yukun Li, Li Yao

и другие.

View, Год журнала: 2025, Номер unknown

Опубликована: Май 8, 2025

Abstract Hepatocellular carcinoma (HCC) is the most commonly occurring liver cancer, and poses a significant burden on individuals, society, economy, healthcare system. Despite advancements in therapeutic options such as surgical interventions targeted therapies, complex etiology clinical presentations of cancer continue to result suboptimal treatment responses. Therefore, identifying more effective methods has become priority HCC research. Targeting programmed cell death protein 1 with immune checkpoint inhibitors significantly improved outcomes; however, these drugs are still limited by their efficacy risk immune‐related adverse reactions, which can death. TIGIT, newly emerging checkpoint, provides novel focus for immunotherapy. The TIGIT/CD155 axis actively reprograms tumor microenvironment (TME), driving carcinogenesis, evasion, metastatic spread. This review systematically elucidates dynamic regulatory networks biological impacts TME, while evaluating its potential through two exploratory strategies: (i) TIGIT have augment anticancer PD‐1/PD‐L1 blockade, (ii) combination regimens integrating TIGIT‐targeted therapies antibody–drug conjugates (ADCs) or chimeric antigen receptor macrophages (CAR‐Ms) could represent viable approach overcoming limitations inherent monotherapy.

Язык: Английский

The regulatory effects and applications of TIGIT/CD155 on the tumor microenvironment in HCC DOI Creative Commons
W. Li, Yukun Li, Li Yao

и другие.

View, Год журнала: 2025, Номер unknown

Опубликована: Май 8, 2025

Abstract Hepatocellular carcinoma (HCC) is the most commonly occurring liver cancer, and poses a significant burden on individuals, society, economy, healthcare system. Despite advancements in therapeutic options such as surgical interventions targeted therapies, complex etiology clinical presentations of cancer continue to result suboptimal treatment responses. Therefore, identifying more effective methods has become priority HCC research. Targeting programmed cell death protein 1 with immune checkpoint inhibitors significantly improved outcomes; however, these drugs are still limited by their efficacy risk immune‐related adverse reactions, which can death. TIGIT, newly emerging checkpoint, provides novel focus for immunotherapy. The TIGIT/CD155 axis actively reprograms tumor microenvironment (TME), driving carcinogenesis, evasion, metastatic spread. This review systematically elucidates dynamic regulatory networks biological impacts TME, while evaluating its potential through two exploratory strategies: (i) TIGIT have augment anticancer PD‐1/PD‐L1 blockade, (ii) combination regimens integrating TIGIT‐targeted therapies antibody–drug conjugates (ADCs) or chimeric antigen receptor macrophages (CAR‐Ms) could represent viable approach overcoming limitations inherent monotherapy.

Язык: Английский

Процитировано

0